StemRIM Inc. (JP:4599) has released an update.
StemRIM Inc. has secured a patent in China for the peripheral peptides of Redasemtide, a key development candidate in their ‘Regeneration-Inducing Medicine’ portfolio. The patent protects against the creation of generics and strengthens StemRIM’s position in China’s rapidly growing pharmaceutical market, which is projected to be worth up to $215 billion by 2028. The move is expected to have minimal financial impact in the current fiscal year but is a strategic step in the global expansion of their regenerative medicine products.
For further insights into JP:4599 stock, check out TipRanks’ Stock Analysis page.
